

Supplementary Appendix 6. Clinical outcome across the studies

References	Year	Comparison	Sample size			Total osteoporotic fracture						Hip fracture					
			VKA	D	R	A	E	VKA	D	R	A	E	VKA	D	R	A	E
Lau et al. [23]	2020	DOAC vs. VKA	9,541	6,867	3,866	3,241	-	196	95	57	53	-	-	-	-	-	-
Binding et al. [35]	2019	DOAC vs. VKA	12,168	25,182	-	-	-	329	606	-	-	-	134	280	-	-	-
Huang et al. [36]	2020	DOAC vs. VKA	9,707	5,833	8,474	1,803	-	1,009	535	530	89	-	-	-	-	-	-
Lutsey et al. [21]	2020	DOAC vs. VKA	82,625	31,647	35,252	17,751	-	3,944	1,771	1,160	419	-	461	182	130	44	-
Lau et al. [19]	2017	DOAC (D) vs. VKA	4,884	3,268	-	-	-	95	34	-	-	-	-	-	-	-	-
Connolly et al. [13]	2009	DOAC (D) vs. VKA	6,021	6,011 (110 mg) 6,075 (150 mg)	-	-	-	34/5,998	43/6,059	-	-	-	-	-	-	-	-
Patel et al. [14]	2011	DOAC (R) vs. VKA	7,133	-	7,131	-	-	115/7,125	-	81/7,111	-	-	-	-	-	-	-
Hori et al. [15]	2012	DOAC (R) vs. VKA	639	-	639	-	-	-	-	-	-	-	-	-	-	-	-
Granger et al. [16]	2011	DOAC (A) vs. VKA	9,081	-	-	9,120	-	-	-	-	-	-	-	-	-	-	-
Giugliano et al. [17]	2013	DOAC (E) vs. VKA	7,036	-	-	-	-	233/7,012 7,034 (30 mg)	-	-	-	-	201/7,012	-	-	-	-

DOAC, direct oral anticoagulant; VKA, vitamin K antagonists; D, dabigatran; R, rivaroxaban; R, rivaroxaban; A, apixaban; E, edoxaban.